Eli Lilly and Company enters its August 5 Q2 print having added another 3.8% on the week to $1,220.66 — clearing the previous all-time high and leaving the defensive surge flagged two days ago looking slightly less extreme, though not resolved.
The clearest shift since the prior note is in options. The put/call ratio has pulled back to 1.29 from its July 24 peak of 1.35, which had pushed the reading to within a whisker of the 52-week high of 1.37. At 1.29, the PCR still runs above its 20-day average of 1.19 by roughly one standard deviation — hedging demand remains elevated, just not at the crisis levels of last Thursday. Short interest tells a more ambiguous story. SI % of FF dipped to 1.15% on July 28, down about 2.5% on the day after the spike to 1.17% on July 24. But the weekly change is still up 15%, confirming that shorts built meaningful new positions over the past five sessions. Borrow conditions offer no squeeze pressure whatsoever — availability is essentially unlimited, with over 607 million shares available to lend, and the cost to borrow sits at a trivial 0.44%. Shorts are not being forced out; they are choosing to be here.
The Street entered earnings week in an unusually constructive mood. Target raises have been widespread over the past three weeks, with Citigroup lifting to $1,600, RBC to $1,500, JPMorgan to $1,400, and Morgan Stanley to $1,347 — all maintaining positive ratings. BofA raised to $1,334 on July 10. The consensus mean target of $1,277 now sits just 4.6% above the current price, a narrower buffer than at the start of the month. The formal consensus reads as a hold, but that reflects the structure of the rating distribution rather than the direction of recent analyst activity — the flow of upgrades and target lifts has been decisively bullish. Factor scores broadly support the bull case: EPS surprise ranks in the 78th percentile, 90-day EPS momentum in the 76th, and the short score rank at 75 suggests the borrow market is not generating meaningful headwinds. The trailing P/E of 30x and EV/EBITDA near 24x are the valuation anchors bears cite; the bear case centers on tirzepatide Rx trajectory, Forglipron execution risk, and Medicare pricing exposure — risks that are well-known but hard to size precisely ahead of a print.
The earnings history adds useful framing. The most recent Q1 release on April 30 produced a 13.2% single-day gain, with the five-day move extending to 14.5%. The prior event in May delivered a more modest 2.7% move. The pattern is wide-range — Lilly has shown it can deliver double-digit reactions in either direction, which helps explain why options traders are still holding above-average put protection even as the stock rallies into the event.
Peer performance on the week was broadly supportive: JNJ gained 6.4%, MRK added 4.4%, and AZN rose 3.6% — suggesting sector tailwinds are helping carry Lilly higher rather than the stock moving in isolation. The setup heading into August 5 is now a stock at all-time highs, with options hedging moderating but still elevated, a short base that rebuilt aggressively last week but faces no borrow pressure, and a Street whose target-raising activity over the past three weeks has set expectations firmly above the current price. The key question at the print is whether tirzepatide volume data and any forward guidance meet a bar that has been raised considerably since May.
See the live data behind this article on ORTEX.
Open LLY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
